Blood-brain barrier disruption occurs in the early stages of Alzheimer's disease. Recent
studies indicate a link between blood-brain barrier dysfunction and cognitive decline and …

Alzheimer's disease (AD) is a prevalent neurodegenerative disease characterized by both
amnestic and non-amnestic clinical manifestations. It accounts for approximately 60-70% of …

Targeted protein degradation (TPD) technology is based on a unique pharmacological
mechanism that has profoundly revolutionized medicinal research by overcoming limitations …

It is well known that vascular factors and specific social determinants of health contribute to
dementia risk and that the prevalence of these risk factors differs according to race and sex …

Alzheimer's disease (AD) is an age‐related degenerative disease of the central nervous
system (CNS), whereas the role of bone marrow immune cells in the pathogenesis of AD …

Parkinson's disease (PD) and Alzheimer's disease (AD) are neurodegenerative disorders
caused by the interaction of genetic, environmental, and familial factors. These diseases …

Abstract Background The prevalence of Alzheimer's disease, the most common type of
dementia, is continuously increasing. Many recent reports have indicated that immune …

Membrane-active peptides (MAPs) possess unique properties that make them valuable tools
for studying membrane structure and function and promising candidates for therapeutic …

Alzheimer's disease (AD) and related dementias constitute an important global health
challenge. Detailed understanding of the multiple molecular mechanisms underlying their …

Alzheimer's disease (AD) causes a significant challenge to global healthcare systems, with
limited effective treatments available. This review examines the landscape of novel …